NVOS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NVOS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Novo Integrated Sciences's Enterprise Value is $15.76 Mil. Novo Integrated Sciences's EBIT for the trailing twelve months (TTM) ended in Feb. 2024 was $-8.97 Mil. Therefore, Novo Integrated Sciences's EV-to-EBIT ratio for today is -1.76.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Novo Integrated Sciences's Enterprise Value is $15.76 Mil. Novo Integrated Sciences's EBITDA for the trailing twelve months (TTM) ended in Feb. 2024 was $-6.66 Mil. Therefore, Novo Integrated Sciences's EV-to-EBITDA ratio for today is -2.37.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Novo Integrated Sciences's Enterprise Value is $15.76 Mil. Novo Integrated Sciences's Revenue for the trailing twelve months (TTM) ended in Feb. 2024 was $13.66 Mil. Therefore, Novo Integrated Sciences's EV-to-Revenue ratio for today is 1.15.
The historical data trend for Novo Integrated Sciences's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novo Integrated Sciences Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Aug17 | Aug18 | Aug19 | Aug20 | Aug21 | Aug22 | Aug23 | |||||||||||
Enterprise Value | Get a 7-Day Free Trial | 100.29 | 96.14 | 53.79 | 62.47 | 25.80 |
Novo Integrated Sciences Quarterly Data | ||||||||||||||||||||
May19 | Aug19 | Nov19 | Feb20 | May20 | Aug20 | Nov20 | Feb21 | May21 | Aug21 | Nov21 | Feb22 | May22 | Aug22 | Nov22 | Feb23 | May23 | Aug23 | Nov23 | Feb24 | |
Enterprise Value | Get a 7-Day Free Trial | 21.13 | 22.96 | 25.80 | 23.45 | 15.59 |
For the Medical Care Facilities subindustry, Novo Integrated Sciences's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Healthcare Providers & Services industry and Healthcare sector, Novo Integrated Sciences's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Novo Integrated Sciences's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Novo Integrated Sciences's Enterprise Value for the fiscal year that ended in Aug. 2023 is calculated as
Enterprise Value (A: Aug. 2023 ) | |||||
= | Market Cap | + | Preferred Stock | + | Long-Term Debt & Capital Lease Obligation |
= | 22.06302 | + | 0 | + | 1.759 |
+ | Short-Term Debt & Capital Lease Obligation | + | Minority Interest | - | Cash, Cash Equivalents, Marketable Securities |
+ | 2.713 | + | -0.317 | - | 0.416 |
= | 25.80 |
Novo Integrated Sciences's Enterprise Value for the quarter that ended in Feb. 2024 is calculated as
Enterprise Value (Q: Feb. 2024 ) | |||||
= | Market Cap | + | Preferred Stock | + | Long-Term Debt & Capital Lease Obligation |
= | 11.19740247 | + | 0 | + | 1.703 |
+ | Short-Term Debt & Capital Lease Obligation | + | Minority Interest | - | Cash, Cash Equivalents, Marketable Securities |
+ | 3.638 | + | -0.298 | - | 0.652 |
= | 15.59 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novo Integrated Sciences (NAS:NVOS) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Novo Integrated Sciences's EV-to-EBIT for today is
EV-to-EBIT | = | Enterprise Value (Today) | / | EBIT (TTM) |
= | 15.761 | / | -8.965 | |
= | -1.76 |
Novo Integrated Sciences's current Enterprise Value is $15.76 Mil.
Novo Integrated Sciences's EBIT for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.97 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Novo Integrated Sciences's EV-to-EBITDA for today is:
EV-to-EBITDA | = | Enterprise Value (Today) | / | EBITDA(TTM) |
= | 15.761 | / | -6.661 | |
= | -2.37 |
Novo Integrated Sciences's current Enterprise Value is $15.76 Mil.
Novo Integrated Sciences's EBITDA for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.66 Mil.
3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.
Novo Integrated Sciences's EV-to-Revenue for today is:
EV-to-Revenue | = | Enterprise Value (Today) | / | Revenue (TTM) |
= | 15.761 | / | 13.658 | |
= | 1.15 |
Novo Integrated Sciences's current Enterprise Value is $15.76 Mil.
Novo Integrated Sciences's Revenue for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $13.66 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Novo Integrated Sciences's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Sarfaraz Ali | director | C/O NOVO INTEGRATED SCIENCES, INC.,, 11120 NE 2ND STREET, SUITE 100, BELLEVUE WA 98004 |
Robert Letterio Oliva | director | 115 BELFIELD RD, TORONTO A6 L0J 1C0 |
Sterling M. Jimenez | officer: Principal Financial Officer | C/O NOVO INTEGRATED SCIENCES, INC.,, 11120 NE 2ND STREET, SUITE 100, BELLEVUE WA 98004 |
Michael Ross Pope | director | 1045 PROGRESS CIRCLE, LAWRENCEVILLE, GEORGIA GA 30043 |
Alex Flesias | director | 41 LANDMARK COURT, UNIONVILLE A6 L3R 9N7 |
Michael Joseph Gaynor | director | 49 BALMORAL ST, KEMPTVILLE A6 K0G 1J0 |
Robert Mattacchione | director, 10 percent owner, officer: Chief Executive Officer | 79 SELVAPIANO CRES, WOODBRIDGE A6 L4H 0X1 |
Pierre Joseph Dalcourt | director, 10 percent owner | 35 BRYANT ST , BOX 2230, HEARST A6 P0L 1N0 |
Christopher Mehlin David | director, officer: President | 10425 SE 22ND ST., BELLEVUE WA 98004 |
Thomas Edward Bray | officer: Principal Financial Officer | C/O NOVO INTEGRATED SCIENCES, INC., 11120 NE 2ND STREET, SUITE 100, BELLEVUE WA 98004 |
Rebecca Aw Mcdonald | officer: Chief Accounting Officer | 1301 INTERNATIONAL SPEEDWAY BLVD., DELAND FL 32724 |
James Jr Teters | director | 1200 FLIGHTLINE BLVD, STE 5, DELAN FL 32724 |
Phyllis Rouse | officer: secretary | 1200 FLIGHLINE BLVD,, SUITE 5, DELAND FL 32724 |
Jay Hilden | officer: President & CEO | 1200 FLIGHLINE BLVD,, SUITE 5, DELAND FL 32724 |
Robert Adamo | director | 1200 FLIGHTLINE BOULEVARD, SUITE 5, DELAND FL 32724 |
From GuruFocus
By Business Wire Business Wire • 10-25-2022
By Business Wire • 12-05-2023
By Business Wire • 08-22-2023
By Business Wire Business Wire • 06-06-2023
By Business Wire Business Wire • 08-09-2022
By Business Wire • 08-31-2023
By Business Wire • 12-04-2023
By Business Wire Business Wire • 10-14-2022
By Business Wire • 09-08-2023
By Business Wire • 07-17-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.